BioXcel submits Phase 3 protocol for BXCL501 in Alzheimer's agitation to FDA

BioXcel Therapeutics, Inc.

Submitted TRANQUILITY In-Care Phase 3 protocol for 60 mcg BXCL501 to FDA on Sept 5, 2024.
Trial targets agitation associated with Alzheimer's dementia.
No additional details on trial design or timeline were disclosed.

item 8.01

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-098149

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.